DSIP

Delta Sleep-Inducing Peptide

Rank#999
SleepNot ApprovedAnimalResearchSubQIntranasal

Popular for:Sleep quality, stress reduction, pain modulation

346

Total Studies

88

Human Studies

Animal

Evidence Level

Not Approved

FDA Status

Overview

DSIP (Delta Sleep-Inducing Peptide) is a 9-amino acid neuropeptide first isolated from rabbit brain in 1977 during sleep research. It is named for its ability to promote slow-wave delta sleep, the deepest and most restorative phase of the sleep cycle.

DSIP crosses the blood-brain barrier and has been studied for its effects on sleep architecture, stress hormone modulation, and pain perception. Research has been conducted primarily in European academic institutions, with some clinical studies in humans demonstrating improved sleep efficiency and reduced sleep latency.

Mechanism of Action

DSIP modulates sleep architecture through multiple mechanisms: it influences serotonergic and GABAergic neurotransmission, reduces cortisol and CRH (corticotropin-releasing hormone) levels, and may affect melatonin secretion timing. Its sleep-promoting effects appear to normalize disrupted sleep patterns rather than inducing sedation, distinguishing it from pharmacological sleep aids.

Key Research Benefits

Promotes slow-wave delta sleep (deep restorative sleep)
Studied for improved sleep efficiency and reduced sleep latency
Researched for stress hormone (cortisol, CRH) reduction
May support pain modulation and analgesic effects
Does not cause sedation — normalizes sleep architecture

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

346

Total Studies

88

Human Studies

Not FDA-approved. Research compound. Studied in European academic settings since 1977. Some human clinical data available. Not scheduled.

Key Studies / PubMed References

346 studies found on PubMed · showing top 25 by relevance

View all on PubMed

secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.

Animal Study

Mu X, Qu L, Yin L, et al. · Frontiers in pharmacology · 2024

PMID: 39444618

Delta sleep-inducing peptide (DSIP): a still unresolved riddle.

In Vitro

Kovalzon VM, Strekalova TV · Journal of neurochemistry · 2006

PMID: 16539679

Antiepileptic activity of delta sleep-inducing peptide and its analogue in metaphit-provoked seizures in rats.

Animal Study

Stanojlović OP, Zivanović DP, Mirković SD, et al. · Seizure · 2005

PMID: 15911358

[Experimental models of epilepsy].

Human Study

Stanojlović OP, Zivanović DP · Medicinski pregled · 2004

PMID: 15626293

Biochemical regulation of non-rapid-eye-movement sleep.

Review

Obal F, Krueger JM · Frontiers in bioscience : a journal and virtual library · 2003

PMID: 12700031

Side Effects & Safety

Headache
Mild next-day grogginess (uncommon)
Injection site reactions
Limited standardization in available research compounds

Known Interactions

No curated interaction entry is live for DSIP yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. DSIP is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.